Jasper Therapeutics filings document a clinical-stage biotechnology issuer developing briquilimab for mast cell driven diseases. Recent Form 8-K reports furnish quarterly and year-end financial results, corporate updates, briquilimab clinical data in chronic spontaneous urticaria and related extension studies, asthma study disclosures, and executive leadership changes.
The filings also identify Nasdaq-listed voting common stock under JSPR and redeemable warrants under JSPRW, and include material-event disclosures involving capital structure, material agreements, shareholder voting matters and corporate reorganization actions tied to the company's operating plan.
Jasper Therapeutics reported first quarter 2026 results and a corporate update centered on its briquilimab program for mast cell diseases such as chronic spontaneous urticaria. The company recorded a net loss of $1,174 thousand for the quarter, significantly lower than $21,241 thousand a year earlier, as research and development expenses fell to $5,814 thousand from $16,157 thousand and general and administrative costs edged down to $5,138 thousand from $5,645 thousand.
Total operating expenses were $10,952 thousand, offset in part by $9,640 thousand of non-cash income from a change in fair value of warrant liability, which contributed to the smaller loss. Cash and cash equivalents were $14,144 thousand as of March 31, 2026, down from $28,692 thousand at December 31, 2025. Jasper is refining its Phase 2b briquilimab trial design in CSU, plans to start the study in the second half of the year, and explicitly notes an imminent need to raise additional funding and risks to its ability to continue as a going concern and to execute the Phase 2b/3 program.
Jasper Therapeutics, Inc. received an amended Schedule 13G/A disclosing that Morgan Stanley and Morgan Stanley Capital Services LLC each report beneficial ownership below 5% of Voting Common Stock. The filing shows 1,333,420 shares (4.8%) attributed to Morgan Stanley and 1,294,420 shares (4.6%) attributed to Morgan Stanley Capital Services LLC, with both entities stating they have ceased to be beneficial owners of more than five percent.
Jasper Therapeutics, Inc. ownership tables show Soleus-related entities collectively report beneficial ownership of up to 276,312 shares, representing 1.0% of common stock. The filing ties the percentage to 27,996,819 shares outstanding as of March 25, 2026.
The report lists holdings by multiple Soleus entities and Guy Levy and includes standard disclaimers that the entities disclaim beneficial ownership except for Section 13(d) purposes.
Jasper Therapeutics Inc ownership disclosure: an amendment to a Schedule 13G/A reports that The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC collectively hold 128,862 shares of Jasper Therapeutics voting common stock, representing 0.5% of the class. The filing is a joint filing under a Joint Filing Agreement and attributes the reported position to Goldman Sachs reporting units and subsidiary arrangements.
Jasper Therapeutics files an amendment to its annual report to add detailed Part III disclosures on governance, executive pay, ownership and related-party transactions. The update does not change financial statements and instead refreshes information on directors, board committees and leadership roles, including CEO Jeet Mahal and Executive Chairperson Tom Wiggans.
The filing highlights 2025 compensation for senior executives, with Jeet Mahal earning a $498,000 salary, a $112,050 bonus and $679,549 in option awards, and CFO Herb Cross receiving similar pay levels. It also describes equity incentive plans, director retainers and options, severance and change-in-control protections, an insider trading policy that bans hedging and pledging, and a Nasdaq-compliant clawback policy for erroneously awarded incentive compensation.
Jasper Therapeutics reported its fourth quarter and full-year 2025 results and provided a corporate update focused on briquilimab, its antibody therapy for mast cell–driven diseases such as chronic urticaria and asthma. For 2025, operating expenses were $83.9 million, driven by $63.1 million in research and development and $20.8 million in general and administrative costs. Net loss for 2025 was $75.8 million compared with $71.3 million in 2024, reflecting continued investment in clinical programs. As of December 31, 2025, Jasper held $28.7 million in cash and cash equivalents, down from $71.6 million a year earlier, and reported total assets of $35.8 million and stockholders’ equity of $4.2 million. The company plans to begin enrolling patients in the Phase 2b portion of a planned Phase 2b/3 chronic spontaneous urticaria study in the second half of 2026, pending capital availability.
Jasper Therapeutics, Inc. files its annual report outlining progress on briquilimab, a monoclonal antibody targeting mast cell driven diseases such as chronic spontaneous urticaria, chronic inducible urticaria and asthma. The company highlights positive early-stage clinical data, a shift of resources away from stem cell transplant uses, and a strategy to build a focused mast cell therapeutics franchise.
Jasper holds worldwide rights to briquilimab under exclusive licenses from Amgen and Stanford, supported by patent families expected to expire in 2027 with newer applications potentially extending protection into the 2040s. The report also details regulatory pathways, manufacturing via Lonza, competitive landscape, and substantial ongoing funding needs with a history of operating losses and going-concern risk.
Jasper Therapeutics, Inc. reported Schedule 13G filings showing shared voting and dispositive power by several Millennium-related entities and an affiliate. Integrated Core Strategies (US) LLC reports shared voting and dispositive power over 1,624,076 shares (5.8%).
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report shared voting and dispositive power over 1,629,013 shares (5.8% each). The filings include a Joint Filing Agreement dated 02/24/2026.
Jasper Therapeutics received an Amendment No. 4 to a Schedule 13D from a group of Carlyle- and Abingworth-affiliated entities updating their ownership in its voting common stock. The group reports beneficial ownership of 1,088,310 shares of common stock, representing 3.8% of the class, based on 27,984,039 shares outstanding as of November 6, 2025. The filing notes that, as of this amendment, the reporting persons have ceased to be beneficial owners of more than five percent of Jasper’s outstanding common stock and that they have not effected any transactions in the stock during the past 60 days. Voting and dispositive power over these shares is shared among the affiliated investment entities.